<DOC>
	<DOC>NCT01009190</DOC>
	<brief_summary>Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors</brief_summary>
	<brief_title>A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens</brief_title>
	<detailed_description />
	<mesh_term>Rucaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1 Patients with acceptable renal, hepatic, and bone marrow function Symptomatic and/or unstable brain metastases, Any cancer treatment within 4 weeks from study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Dose finding PARPi Chemotherapy</keyword>
</DOC>